Azd-1152hqpa

Base Information

• Chemical Name: Azd-1152hqpa
• CAS No.: 722544-51-6
• Molecular Formula: C26H30FN7O3
• Molecular Weight: 507.568
• UNII: 29P8LWS24N
• ChEMBL ID: CHEMBL215152
• DSSTox Substance ID: DTXSID60222584
• NCI Thesaurus Code: C179080
• Nikkaji Number: J2.809.313F,J2.770.488C
• Wikidata: Q27074868
• Mol file: 722544-51-6.mol

Synonyms:2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide;AZD2811

Chemical Property of Azd-1152hqpa

Chemical Property:

• Vapor Pressure: 9.07E-27mmHg at 25°C
• Refractive Index: 1.677
• Boiling Point: 796.7 °C at 760 mmHg
• PKA: 13.07±0.10(Predicted)
• Flash Point: 435.6 °C
• PSA: 128.29000
• Density: 1.359 g/cm³
• LogP: 3.64590
• Storage Temp.: 2-8°C
• Solubility.: DMSO: >15mg/mL
• XLogP3: 3
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 13
• Exact Mass: 507.23941601
• Heavy Atom Count: 37
• Complexity: 693

Purity/Quality:

98%,99%, ^*data from raw suppliers

AZD1152-HQPA ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
• Recent ClinicalTrials: Study of AZD2811 + Durvalumab in ES-SCLC
• Recent EU Clinical Trials: A Phase II Multicenter, Open-Label, Single Arm Study to
• Description: AZD1152-HQPA (722544-51-6) is a potent and highly selective inhibitor of Aurora B.1?Aurora B Ki?= 0.36 nM; Aurora A Ki?= 1,369 nM.2?It inhibits the growth of tumors in multiple cancer models.3-6?Excessive ROS generation7?and upregulated tumor suppressor miRNAs8?have been proposed as a novel mechanisms of cytotoxicity of AZD1152-HQPA.
• Uses: AZD1152-HQPA is a a highly selective inhibitor of aurora-B kinase. AZD1152-HQPA has been shown to inhibit osteosarcoma cell line U2-OS cells proliferation. AZD1152-HQPA was also shown to be an effective apoptosis-inducing agent in acute myeloid leukemia cell lines and primary acute myeloid leukemia cultures. AZD1152-HQPA has been used:for the dose dependent inhibition of aurora kinase B (AURKB)as a component to identify that, replication timing regulatory factor 1 (RIF1) and protein phosphatase 1 (PP1) are critical for the regulation of abscission timing in human cellsas a component to study the relevance of AURKB as a cancer therapeutic target

Technology Process of Azd-1152hqpa

There total 16 articles about Azd-1152hqpa which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 85.0%

2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide (722544-46-9) + 2-(Ethylamino)ethanol (110-73-6) → N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide (722544-51-6)

Guidance literature:

In N,N-dimethyl acetamide; at 90 ℃; for 12 - 16h;

Reference yield: 59.0%

→ N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide (722544-51-6)

Guidance literature:

Reference yield:

4-chloro-7-hydroxyquinazoline (849345-42-2) → 2-{5-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-3-yl}-N-(3-fluorophenyl)acetamide (1218904-24-5,722544-51-6)

Guidance literature:

Multi-step reaction with 5 steps

1: copper(I) oxide; ammonia / 200 °C / 60006 Torr

2: sulfuric acid / Heating

3: tetra(n-butyl)ammonium hydrogensulfate; sodium hydroxide / water

4: tetra(n-butyl)ammonium hydrogensulfate; sodium hydroxide / water

5: tetra(n-butyl)ammonium hydrogensulfate; sodium hydroxide / water

With copper(I) oxide; sulfuric acid; ammonia; tetra(n-butyl)ammonium hydrogensulfate; sodium hydroxide; In water;

upstream raw materials:

2-(5-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-2H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide

2-(Ethylamino)ethanol

(5-amino-2H-pyrazol-3-yl)acetic acid

4-(3-phenylpropylamino)-7-(2-chloroethoxy)quinazoline

Downstream raw materials:

di-tert-butyl 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl phosphate

2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)proplyl]amino}ethyl dihydrogen phosphate

Refernces

• 1、 -. "PROCESS AND INTERMEDIATE". Page/Page column 9; 11. . Retrieved 2008/06/13.
• 2、 -. "COMBINATION THERAPY FOR THE TREATMENT OF CANCER". Page/Page column 25-26. . Retrieved 2008/06/13.